[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anterior-circulation-brain-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anterior-circulation-brain-infarction":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,76,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100622641","a-trial-of-adacolumn-on-cerebral-edema-after-anterior-circulation-ischemic-stroke-100622641",false,"NCT07386262","A Trial of Adacolumn on Cerebral Edema After Anterior Circulation Ischemic Stroke","Efficacy and Safety of the Adacolumn® Granulocyte and Monocyte\u002FMacrophage Apheresis Device for Cerebral Edema After Acute Anterior Circulation Occlusive Cerebral Infarction: A Prospective, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age 18-80 years, regardless of gender;\n2. A clinical diagnosis of acute ischemic stroke;\n3. Proven large vessel occlusion in ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions) determined by MRA or CTA or DSA;\n4. NIHSS score ≥10 at screening;\n5. Pre-stroke mRS score \\\u003C2 (independent in all activities of daily living);\n6. Time from stroke onset to initiation of the first Adacolumn treatment is ≤24 hours, stroke onset is defined as the last time the patient was known to be at their neurological baseline (wake-up strokes qualify if within this time window);\n7. All endovascular thrombectomy and\u002For intravenous thrombolysis must strictly adhere to the \"2024 Chinese Stroke Association Guidelines for Reperfusion Therapy in Acute Ischemic Stroke\" and the latest prescribing information regarding indications, contraindications, and procedural standards;\n8. Written informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Decompressive craniectomy performed before enrollment or between enrollment and initiation of study treatment;\n2. After endovascular thrombectomy: extensive contrast extravasation (diffuse subarachnoid high density or parenchymal high density not consistent with hematoma), new subarachnoid hemorrhage（SAH）, or symptomatic intracranial hemorrhage (sICH);\n3. Large-vessel occlusion is attributed to other determined etiologies per TOAST classification, such as tumor-related, dissection-related, or other clearly identifiable non-LAA\u002Fnon-CE causes.\n4. Clinical signs of brain herniation, such as unilateral or bilateral fixed dilated pupils and\u002For other loss of brainstem reflexes attributable to cerebral edema or herniation in the investigator's opinion;\n5. Intracranial lesions conferring markedly increased bleeding risk (known brain tumor, arteriovenous malformation, aneurysm);\n6. Inability to undergo MRI;\n7. Absolute neutrophil count \\\u003C1.5×10⁹\u002FL or \\>15×10⁹\u002FL\n8. Absolute monocyte count \\> 1.0 ×10⁹\u002FL;\n9. Red blood cells \\\u003C3.0×10¹²\u002FL ;\n10. Active internal bleeding or bleeding tendency (such as platelet count \\\u003C100×10⁹\u002FL, INR \\>1.7, PT \\>15 seconds);\n11. Marked hypercoagulability (fibrinogen \\>700 mg\u002FdL);\n12. Intracranial or spinal surgery or severe head trauma within the past 3 months;\n13. Refractory hypertension (persistent systolic blood pressure \\>185 mmHg or diastolic \\>110 mmHg);\n14. Known allergy to components of the blood purification system (including adsorption membrane, anticoagulants);\n15. Acute ST-segment elevation myocardial infarction and\u002For acute decompensated heart failure and\u002For corrected QT interval \\>520 ms and\u002For history of cardiac arrest within the past 6 months(pulseless electrical activity, ventricular tachycardia, ventricular fibrillation, or asystole);\n16. Body temperature \\>38°C or active infection;\n17. Active autoimmune disease or immunodeficiency;\n18. Participation in another interventional clinical trial within the past 30 days;\n19. Any other condition deemed unsuitable for participation by the investigator.","ALL","18 Years","80 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary objective is to investigate whether treatment with Adacolumn can ameliorate the progression of cerebral edema within 72 hours in patients with anterior circulation ischemic stroke. The secondary objective is to explore if Adacolumn could improve acute neurologic status, functional outcomes, treatment requirements and safety in patients with anterior circulation ischemic stroke.",[27,28,29,30],"Cerebral Edema","Ischemic Stroke, Acute","Malignant Cerebral Edema","Anterior Circulation Brain Infarction","NOT_YET_RECRUITING","2026-08-04",{"date":34,"type":35},"2026-08-07","ACTUAL",{"date":37,"type":21},"2026-08-10",{"date":39,"type":21},"2028-12-31",{"name":41,"class":42},"Second Affiliated Hospital, Zhejiang University, School of Medicine","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100650474","phase-3-tenecteplase-or-reteplase-as-bridging-thrombolysis-before-thrombectomy-in-acute-ischemic-cerebrovascular-events-100650474","NCT07748039","Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events","Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events (TRACE-BRIDGE): A Multicenter, Randomized, Open-Label, Three-Arm, Blinded-Endpoint Phase III Trial","TRACE- BRIDGE","Inclusion Criteria:\n\n1. Patients with acute ischemic stroke presenting within 4.5 hours of symptom onset who are eligible for intravenous thrombolytic therapy. A baseline non-contrast CT or MRI is required for screening.\n2. Large vessel occlusion on computed tomographic angiography (CTA) or magnetic resonance angiography (MRA) of the intracranial carotid artery (ICA) or middle cerebral artery (MCA) M1\n3. Age ⩾ 18 years at the time of signing the informed consent form\n4. ASPECTS 6-10\n5. Informed consent from the patients or their legal representative.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage (ICH) identified by CT or MRI\n2. Rapidly improving symptoms at the discretion of the investigator\n3. mRS \\> 2 before stroke onset.\n4. Massive cerebral infarction (infarct size greater than one-third of the blood middle cerebral artery supply area) suggested by CT.\n5. Known contraindication to imaging with contrast agents\n6. Planned adjunct intra-arterial (IA) thrombolysis during or after endovascular treatment (EVT).\n7. Secondary transfer from a primary stroke center\n8. Any terminal illness such that patient would not be expected to survive more than one year\n9. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study\n10. Pregnant women",{"count":53,"type":21},1440,[55],"PHASE3","Acute ischemic stroke caused by large vessel occlusion (LVO) is a major cause of disability, and mechanical thrombectomy (MT) has become the standard treatment for eligible patients. However, the optimal role of intravenous thrombolysis before MT remains uncertain.\n\nThe TRACE-BRIDGE trial is a phase 3, investigator-initiated, multicenter, randomized, open-label trial with blinded outcome assessment (PROBE design) evaluating different bridging thrombolysis strategies before MT. The trial will enroll adults with acute ischemic stroke presenting within 4.5 hours of symptom onset and with imaging-confirmed anterior circulation LVO who are eligible for intravenous thrombolysis and MT.\n\nParticipants will be randomly assigned in a 1:1:1 ratio to receive tenecteplase plus MT, reteplase plus MT, or direct MT alone. The TRACE-BRIDGE trial aims to evaluate the efficacy and safety of bridging thrombolysis with tenecteplase or reteplase before mechanical thrombectomy compared with direct mechanical thrombectomy. The primary outcome is functional independence, defined as a modified Rankin Scale score of 0-2 at 90 days after randomization. If superiority of bridging thrombolysis is demonstrated, the trial will further evaluate whether reteplase is non-inferior to tenecteplase as a bridging thrombolytic strategy.",[58,59,30],"Acute Ischemic Stroke","Large Vessel Occlusion",[61,62,63,64,65],"acute ischemic stroke","thrombolysis","thrombectomy","tenecteplase","reteplase","2026-08-03",{"date":68,"type":35},"2026-08-05",{"date":70,"type":21},"2026-08-01",{"date":72,"type":21},"2029-08-01",{"name":74,"class":42},"Yongjun Wang",5,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":43},"100637603","phase-2-minocycline-after-successful-endovascular-thrombectomy-recanalization-in-acute-anterior-circulation-large-vessel-occlusion-attraction-minoa-100637603","NCT07594314","Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA)","Safety and Efficacy of Adjunctive Minocycline After Successful Endovascular Thrombectomy Recanalization for Acute Anterior Circulation Large Vessel Occlusion - A Multicenter, Prospective, Double-blind, Randomized Trial","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Pre-stroke mRS score of 0-1;\n3. Time from symptom onset to randomization ≤24 hours, including wake-up stroke or unwitnessed stroke. Symptom onset is defined as the last known well time;\n4. Baseline NIHSS score of 6-25;\n5. ASPECTS ≥6 on non-contrast CT or DWI;\n6. Clinical symptoms attributable to acute occlusion at one of the following sites, confirmed by CTA, MRA, or DSA: intracranial internal carotid artery, M1 segment of the middle cerebral artery, or M2 trunk of the MCA;\n7. Successful recanalization defined as mTICI 2b-3 after mechanical thrombectomy, with no evidence of secondary embolization in non-target vessels; or spontaneous improvement to mTICI 2b-3 on diagnostic angiography prior to thrombectomy with no planned intervention;\n8. Ability of the patient or legally authorized representative to provide written informed consent.\n\nExclusion Criteria:\n\n1. Acute intracranial hemorrhage on CT or MRI;\n2. Bilateral acute stroke or multiple intracranial large vessel occlusions;\n3. Isolated extracranial internal carotid artery occlusion;\n4. History of pseudomembranous colitis or antibiotic-associated colitis;\n5. Known allergy to tetracycline antibiotics, any component of the investigational drug, radiocontrast agents, or nitinol materials;\n6. Known resistance to tetracycline antibiotics;\n7. Use of tetracycline antibiotics within 7 days prior to randomization;\n8. History of intracranial hemorrhage within the past 3 months, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma;\n9. Intracranial tumors, vascular malformations, or other space-occupying intracranial lesions;\n10. History of intracranial or spinal surgery within the past 3 months;\n11. History of major surgery or significant trauma within the past 1 month;\n12. Receipt of any of the following treatments within the past 3 months: systemic retinoic acid or androgen\u002Fantiandrogen therapy (e.g., anabolic steroids, spironolactone);\n13. Platelet count \\\u003C100 × 10⁹\u002FL;\n14. Severe hepatic insufficiency, chronic hemodialysis, or severe renal insufficiency (defined as estimated glomerular filtration rate \\\u003C30 mL\u002Fmin or serum creatinine \\>265.2 μmol\u002FL \\[3.0 mg\u002FdL\\]);\n15. Women who are pregnant or lactating, or who have a positive pregnancy test prior to randomization;\n16. Life expectancy \\\u003C6 months (e.g., due to malignancy or severe cardiopulmonary disease);\n17. Participation in another interventional clinical trial that may affect outcome assessment;\n18. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation or poses significant risk (e.g., inability to understand or comply with study procedures or follow-up due to psychiatric, cognitive, or emotional disorders).",{"count":84,"type":21},860,[86,55],"PHASE2","Endovascular thrombectomy (EVT) improves outcomes in patients with acute large vessel occlusion (LVO). However, despite successful recanalization rates exceeding 80%, fewer than 50% of patients achieve favorable functional outcomes at 90 days, indicating a high rate of futile recanalization. Potential mechanisms include no-reflow, reperfusion injury, and microcirculatory dysfunction, which are closely associated with post-recanalization neuroinflammation.\n\nMinocycline is a second-generation tetracycline with pleiotropic neuroprotective effects, including inhibition of microglial activation, reduction of inflammatory mediators, suppression of matrix metalloproteinases, attenuation of oxidative stress, and preservation of blood-brain barrier integrity. Prior preclinical and clinical studies suggest that minocycline may improve neurological outcomes in acute ischemic stroke.\n\nThis study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate the safety and efficacy of adjunctive minocycline in patients with acute anterior circulation LVO who achieve successful recanalization after EVT. The trial will assess whether early administration of minocycline improves functional outcomes and reduces futile recanalization.",[58,89,90,30,91],"Vessel Occlusion","Endovascular Thrombectomy","Minocycline",[58,90,91,93],"Anterior Circulation Large Vessel Occlusion","RECRUITING","2026-05-22",{"date":97,"type":35},"2026-05-27",{"date":99,"type":35},"2026-05-21",{"date":101,"type":21},"2028-12",{"name":103,"class":42},"Xiang Luo",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100559062","phase-3-remote-ischemic-conditioning-for-acute-ischemic-stroke-treated-with-mechanical-thrombectomyrecast-mt-100559062","NCT06559241","Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy（RECAST-MT）","Safety and Efficacy of Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy (RECAST-MT): A Multicenter, Randomized, Controlled, Open-label, Blinded Endpoint Trial","RECAST-MT","Inclusion Criteria:\n\n1. Age≥18 years；\n2. Acute ischemic stroke due to large vessel occlusion in the anterior circulation that is not suitable for intravenous thrombolytic therapy, or has contraindications to intravenous thrombolytic therapy, or treated with intravenous thrombolytic therapy without recanalization;\n3. Large vessel occlusion confirmed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA), including the occlusion of the intracranial segment of the internal carotid artery (ICA) and M1 segment of the middle cerebral artery (MCA), is the cause of symptoms, and mechanical thrombectomy is planned within 24 hours from the time last known well;\n4. Baseline score of the National Institutes of Health Stroke Scale (NIHSS) ≥ 6 points;\n5. Patients or family members signed a written informed consent form.\n\nExclusion Criteria:\n\n1. Imaging examination revealed the presence of multiple vascular supply areas of cerebral infarction (such as the simultaneous presence of infarction in both anterior and posterior circulation);\n2. Absence of femoral artery pulsation, extremely difficult intravascular access, or extremely tortuous large vessels, which are expected to result in the inability to undergo timely endovascular treatment;\n3. Difficult-to-control hypertension: continuous monitoring upon admission shows systolic blood pressure ≥180mmHg, or diastolic blood pressure ≥100mmHg;\n4. Coma or lethargy patients (consciousness level score ≥2 in NIHSS);\n5. Unable to obtain an accurate baseline NIHSS score;\n6. Pre-stroke modified Rankin Scale (mRS) score \\>1;\n7. Baseline ASPECTS score ≤5;\n8. Presence of bleeding tendency, deficiency of coagulation factors, or oral anticoagulant therapy with INR \\> 3.0;\n9. Baseline blood glucose \\\u003C2.7mmol\u002FL or \\>22.2mmol\u002FL;\n10. Baseline platelet count \\\u003C 30\\*10\\^9\u002FL;\n11. Severe known renal impairment defined as requiring dialysis (hemodialysis or peritoneal dialysis), or if known creatinine clearance rate \\\u003C30mL\u002Fmin;\n12. Cranial CT or MRI shows intracranial hemorrhage;\n13. Cranial CT or MRI shows midline deviation and significant occupying effect;\n14. Clinical history, previous imaging examinations, or clinical judgment suggesting intracranial tumors, arteriovenous malformations, or intracranial arterial dissection;\n15. History of head injury in the past 3 months;\n16. History of life-threatening allergy to contrast agents, nickel, titanium metal, or their alloys;\n17. Pregnancy, if women of childbearing age have a positive urinary or serum β-human chorionic gonadotropin (β-hCG) test or are breastfeeding；\n18. The life expectancy of patients is less than 6 months, and they cannot be evaluated within 3 months;\n19. Limb deformity, soft tissue injury, or other conditions that affect the implementation of distant ischemia adaptation therapy;\n20. Participating in other ongoing clinical trials;\n21. Other conditions that the investigators believe are not suitable for participation in this study.",{"count":113,"type":21},2105,[55],"For patients with acute ischemic stroke caused by large vessel occlusion, endovascular thrombectomy has been demonstrated to be the most effective therapy, as approximately 90% of the occluded vessels can be recanalized. However, less than 50% of patients could achieve functional independence, and over 15% died 90 days after stroke. Although the mismatch of successful recanalization with poor prognosis can be attributed to many factors, the infarct core formed during thrombectomy and reperfusion injury after thrombectomy may be among the most important and effective neuroprotective strategies urgently needed.\n\nRemote ischemic conditioning (RIC) is a noninvasive strategy in which one or more cycles of brief and transient limb ischemia confer protection against prolonged and severe ischemia in distant organs. In the transient focal cerebral ischemia-reperfusion model, the application of remote ischemic conditioning before reperfusion or both before and after reperfusion reduces reperfusion injuries and the final infarct size. Because patients with acute ischemic stroke who are treated with endovascular thrombectomy can achieve a high rate of recanalization after focal ischemia, this patient population is akin to the model of transient focal cerebral ischemia-reperfusion. Furthermore, a pilot study has determined the safety and feasibility of remote ischemic conditioning in patients undergoing endovascular thrombectomy. However, whether remote ischemic conditioning could provide clinical benefits to patients with acute ischemic stroke who are treated with endovascular thrombectomy urgently needs investigations.\n\nThis study aims to investigate the safety and efficacy of remote ischemic conditioning in improving functional outcomes of patients with acute ischemic stroke treated with endovascular thrombectomy and explore the effect of treatment duration on the treatment outcome of remote ischemic conditioning.",[58,30],[118,119,120],"Endovascular thrombectomy","Cerebroprotection","Remote ischemic conditioning","2025-12-03",{"date":123,"type":35},"2025-12-10",{"date":125,"type":35},"2024-09-23",{"date":127,"type":21},"2027-02",{"name":129,"class":42},"Capital Medical University",56]